MedTrace Logo

Dietary Fatty Acids As Complementary Therapy in Type 2 Diabetes Mellitus

NCT00607945 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2024-10-29

No results posted yet for this study

Summary

The purpose of the study is to see how a dietary oil called conjugated linoleic acid, or CLA, might be useful in combination with diabetes medication. Some studies show that CLA can modestly reduce body weight and body fat. Our research idea is that taking CLA will reduce body weight and body fat without interfering with the diabetes medications' effects on blood sugar.

Conditions

Interventions

DRUG

Rosiglitazone (Avandia) OR other diabetes medication currently prescribed to participant

Rosiglitazone 4-8mg/day, pill, from week -4 to week 32 OR other diabetes medication taken as prescribed from week -4 to week 32

DIETARY_SUPPLEMENT

conjugated linoleic acid (CLA)

3.2 g/day, capsule, week 0 to week 32

DIETARY_SUPPLEMENT

conjugated linoleic acid (CLA)

6.4 g/day, capsule, week 0 to week 32

Sponsors & Collaborators

  • National Center for Complementary and Integrative Health (NCCIH)

    collaborator NIH

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Bunge Loders Croklaan

    collaborator INDUSTRY

  • LifeScan

    collaborator INDUSTRY

  • Ohio State University

    lead OTHER

Principal Investigators

  • Martha A Belury, PhD, RD · Ohio State University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2012-05-31
Completion
2012-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00607945 on ClinicalTrials.gov